144 related articles for article (PubMed ID: 31164309)
21. Importance of the neutrophil-to-lymphocyte ratio in muscle-invasive and non-muscle invasive bladder tumors.
Ceylan C; Doluoglu OG; Keleş I; Gazel E; Temuçin T; Odabaş Ö; Karalar M
Urologia; 2014; 81(2):120-4. PubMed ID: 24474540
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Mbeutcha A; Shariat SF; Rieken M; Rink M; Xylinas E; Seitz C; Lucca I; Mathieu R; Rouprêt M; Briganti A; Karakiewicz PI; Klatte T
Urol Oncol; 2016 Nov; 34(11):483.e17-483.e24. PubMed ID: 27646875
[TBL] [Abstract][Full Text] [Related]
23. Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.
Ziani I; Ibrahimi A; Zaoui Y; El Sayegh H; Abouqal R; Nouini Y; Bouziane A
Pan Afr Med J; 2023; 44():145. PubMed ID: 37396698
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
Zhang J; Zhou X; Ding H; Wang L; Liu S; Liu Y; Chen Z
BMC Urol; 2020 Mar; 20(1):31. PubMed ID: 32192483
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Nonmuscle-Invasive Bladder Cancer Treated with GreenLight Laser Vaporization.
Luo F; Ma C; Wu J; Li J
Photobiomodul Photomed Laser Surg; 2019 May; 37(5):312-317. PubMed ID: 31084565
[No Abstract] [Full Text] [Related]
27. Can the Preoperative Neutrophil-to-Lymphocyte Ratio Significantly Predict the Conditional Survival Probability in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy?
Kang M; Balpukov UJ; Jeong CW; Kwak C; Kim HH; Ku JH
Clin Genitourin Cancer; 2017 Jun; 15(3):e411-e420. PubMed ID: 28162942
[TBL] [Abstract][Full Text] [Related]
28. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil-to-lymphocyte ratio is elevated in recurringnonmuscle invasive bladder cancer.
Yürük E; Saitz TR; Gönültaş S; Şerefoğlu EC; Müslümanoğlu AY
Turk J Med Sci; 2017 Feb; 47(1):234-239. PubMed ID: 28263495
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
[TBL] [Abstract][Full Text] [Related]
31. Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models.
Choi SY; Ryu JH; Chang IH; Kim TH; Myung SC; Moon YT; Kim KD; Kim JW
Korean J Urol; 2014 Oct; 55(10):643-9. PubMed ID: 25324946
[TBL] [Abstract][Full Text] [Related]
32. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of preoperative pyuria & neutrophil to lymphocyte ratio in patients with non-muscle-invasive bladder cancer: A prospective cohort study.
Singh R; Sharma G; Priyadarshi S; Fauzdar G
Urologia; 2024 Feb; 91(1):69-75. PubMed ID: 37909427
[TBL] [Abstract][Full Text] [Related]
34. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
Zhang G; Steinbach D; Grimm MO; Horstmann M
World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
[TBL] [Abstract][Full Text] [Related]
35. Preoperative neutrophil-to-lymphocyte ratio (NLR) may be predictive of pathologic stage in patients with bladder cancer larger than 3 cm.
Celik O; Akand M; Keskin MZ; Yoldas M; Ilbey YO
Eur Rev Med Pharmacol Sci; 2016; 20(4):652-6. PubMed ID: 26957266
[TBL] [Abstract][Full Text] [Related]
36. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.
Simon M; Bosset PO; Rouanne M; Benhamou S; Radulescu C; Molinié V; Neuzillet Y; Paoletti X; Lebret T
PLoS One; 2019; 14(2):e0211721. PubMed ID: 30811419
[TBL] [Abstract][Full Text] [Related]
37. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
Ravvaz K; Walz ME; Weissert JA; Downs TM
J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
[TBL] [Abstract][Full Text] [Related]
38. The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.
Kishimoto N; Takao T; Kuribayashi S; Yamamichi G; Nakano K; Kawamura M; Tsutahara K; Tanigawa G; Yamaguchi S
Int J Clin Oncol; 2017 Feb; 22(1):153-158. PubMed ID: 27614622
[TBL] [Abstract][Full Text] [Related]
39. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
[TBL] [Abstract][Full Text] [Related]
40. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
